[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633665":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":15,"collaborators":10,"id":19,"slug":20,"hasResults":21,"nctId":22,"briefTitle":23,"officialTitle":24,"acronym":10,"eligibilityCriteria":25,"healthyVolunteers":21,"sex":26,"minAge":10,"maxAge":10,"enrollmentInfo":27,"targetDuration":10,"studyType":30,"phases":10,"briefSummary":31,"conditions":32,"keywords":37,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"pT1 Urothelial Carcinoma Cases",null,"All confirmed pT1 cases will undergo rigorous histopathological substaging. An anatomical substaging (T1a\u002Fb\u002Fc) will be performed by identifying the level of invasion relative to the muscularis mucosae. Additionally, micrometric assessment will be carried out using a 0.1 mm threshold and the Rete Oncologica Lombarda (ROL) system.",{"label":13,"type":10,"description":14,"interventionNames":10},"pT2 Urothelial Carcinoma Cases","These cases will be evaluated for Tumor Budding. The \"Hotspot\" method will be used to count buds in one high power field at the invasive front. Cases will be graded as Low Budding (BD1): 0-4 buds, Intermediate Budding (BD2): 5-9 buds, and High Budding (BD3): ≥ 10 buds.",{"type":16,"investigatorFullName":17,"investigatorTitle":18,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hasnaa Usama Ahmed","Demonstrator of Pathology at South Egypt Cancer Institute, Assiut University","100633665","tumor-budding-and-t1-substaging-in-urothelial-bladder-cancer-100633665",false,"NCT07529639","Tumor Budding and T1 Substaging in Urothelial Bladder Cancer","Assessment of Tumor Budding and T1 Substaging as Histopathological Predictors of Outcome in Urothelial Bladder Carcinoma","Inclusion Criteria:\n\n* Patients with a urinary bladder mass, diagnosed by TUR biopsy as urothelial carcinoma.\n* Patients with full clinical data and complete medical reports.\n\nExclusion Criteria:\n\n* Cases with non-urothelial histological subtypes (e.g., pure squamous cell carcinoma).\n* Patients who received neoadjuvant chemotherapy or radiotherapy.\n* Cases with missing or inaccessible clinical follow-up data.\n* History of prior or concurrent malignancy.","ALL",{"count":28,"type":29},100,"ESTIMATED","OBSERVATIONAL","Bladder cancer is a significant global and local health concern, and predicting how aggressive a patient's tumor will behave is critical for guiding treatment. This observational study aims to evaluate two specific microscopic features of urothelial bladder carcinoma to see if they can reliably predict patient outcomes: the depth of early tumor invasion (T1 substaging) and the presence of small clusters of cancer cells at the tumor's edge (Tumor Budding).\n\nResearchers will retrospectively analyze tissue samples (paraffin blocks) from at least 100 patients who were diagnosed with urothelial bladder carcinoma and underwent transurethral resection (TUR) at the South Egypt Cancer Institute between 2018 and 2024.\n\nThe tissue samples will be analyzed in two main ways:\n\n* Early-stage tumors (pT1 cases): Researchers will carefully measure the exact depth the tumor has invaded the bladder lining using anatomical and micrometric sub-classification systems.\n* More advanced tumors (pT2 cases): Researchers will examine the invasive edge of the tumors under a microscope to count \"tumor buds\" (single cells or small clusters of cells).\n\nBy comparing these detailed microscopic measurements with the patients' historical medical records, the study hopes to determine if T1 substaging and Tumor Budding are strong predictors of disease recurrence, disease progression, and overall patient survival.",[33,34,35,36],"Urothelial Bladder Carcinoma","Bladder Carcinoma","Non-Muscle-Invasive Bladder Cancer (NMIBC)","Muscle-Invasive Bladder Cancer (MIBC)",[38,39,40,41,42,43,44,45],"Tumor Budding","T1 Substaging","Histopathology","Disease Progression","Survival Outcomes","Transurethral Resection (TUR)","Epithelial-Mesenchymal Transition (EMT)","Invasion Depth","NOT_YET_RECRUITING","2026-04-08",{"date":49,"type":50},"2026-04-14","ACTUAL",{"date":52,"type":29},"2026-05",{"date":54,"type":29},"2027-06",{"name":5,"class":6}]